Damian Pharma AG   Report issue

For profit Phase 2
Founded: Walchwil Switzerland (2014)

Organization Overview

First Clinical Trial
2017
NCT03046589
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Damian Pharma AG

Active Ingredients

Drugs in Phase 2 Trials (1)

dp13 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperaldosteronism (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1